You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

r/r MCL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Myopia Trial in Singapore (Myopia Control Lens-1 (MCL1), Myopia Control Lens-2 (MCL2))

Not yet recruiting
  • Myopia
  • Myopia Control Lens-1 (MCL1)
  • Myopia Control Lens-2 (MCL2)
  • Singapore, Singapore
    Essilor R&D Centre Singapore
Nov 27, 2023

Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
Aug 8, 2022

Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma Trial in Guangzhou (Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib

Recruiting
  • Mantle Cell Lymphoma
  • Newly-diagnosed Mantle Cell Lymphoma
  • Zanubrutinib and Rituximab
  • +2 more
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Hodgkin Lymphoma Trial in Belgium, Denmark, Netherlands (gemcitabine, cisplatin and tislelizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • gemcitabine, cisplatin and tislelizumab
  • Brussels, Belgium
  • +14 more
Aug 12, 2022

Lymphoma, Mantle-Cell Trial in Czechia (Polatuzumab vedotin, Bendamustine Hydrochloride, Rituximab)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • Polatuzumab vedotin
  • +2 more
  • Brno, Czechia
  • +6 more
May 28, 2021

Mantle Cell Lymphoma Trial in China (ICP-022)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Hefei, Anhui, China
  • +30 more
Jul 5, 2022

Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Italy (Consolidation with ADCT-402 (loncastuximab

Recruiting
  • Relapsed Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C))
  • Brescia, Italy
  • +19 more
Apr 22, 2022

Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
Mar 23, 2022

Lymphoma, Mantle-Cell Trial in Italy (Venetoclax)

Active, not recruiting
  • Lymphoma, Mantle-Cell
  • Alessandria, Italy
  • +34 more
Aug 1, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Acalabrutinib
  • CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Jun 16, 2022

Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL) Trial in Worldwide (AMG 562)

Completed
  • Diffuse Large B-cell Lymphoma(DLBCL)
  • +2 more
  • AMG 562
  • Duarte, California
  • +11 more
Feb 22, 2022

CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
Jan 20, 2023

Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

Suspended
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jun 7, 2022

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Follicular Lymphoma (FL) Trial (biological, drug, other)

Not yet recruiting
  • Follicular Lymphoma (FL)
  • Tisagenlecleucel
  • +4 more
  • (no location specified)
May 24, 2023

HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and

Not yet recruiting
  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors
  • ADCC-R-Epo-R T-cells + Trastuzumab
  • +2 more
  • (no location specified)
Aug 31, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase

Not yet recruiting
  • B-cell Lymphoma
  • Beijing, Beijing, China
    Deparment of Hematology, Peking University People's Hospital
Aug 9, 2022

Time for R Anastomosis; Complication Related to Anastomosis Trial in Yangzhou (R anastomosis)

Completed
  • Time for R Anastomosis; Complication Related to Anastomosis
  • R anastomosis
  • Yangzhou, Jiangsu, China
    Northern Jiangsu People's Hospital
Apr 11, 2023

Arthritis, Rheumatoid Trial in Lebanon (R-2487)

Not yet recruiting
  • Arthritis, Rheumatoid
  • Lebanon, New Hampshire
    Dartmouth Hitchcock Medical Center (DHMC)
Jul 18, 2023

Non-invasive Continuous Hemodynamic Measurement From Task Force

Not yet recruiting
  • Hemodynamic Measurement
  • +2 more
  • non-invasive device (Task Force CORE(R) and Task Force CARDIO(R)
  • Graz, Styria, Austria
    Medical University of Graz
Aug 23, 2023

B-cell Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin)

Recruiting
  • B-cell Non-Hodgkin Lymphoma
  • Mosunetuzumab (IV)
  • +4 more
  • Birmingham, Alabama
  • +28 more
Jan 6, 2023

Richter Syndrome Trial in United States (Venetoclax, DA-EPOCH-R, R-CHOP)

Recruiting
  • Richter Syndrome
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

Completed
Has Results
  • Non-Hodgkin's Lymphoma, Relapsed
  • +8 more
  • PBCAR20A
  • +2 more
  • Duarte, California
  • +4 more
Jan 4, 2023